The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Subscribe To Our Newsletter & Stay Updated
